Shots:

• Formycon and Bioeq have submitted MAA for FYB201 (biosimilar referencing Lucentis) to EMA
• Teva will responsible for the commercialization of FYB201 in the EU which has acquired the distribution rights under its collaboration with Bioeq. Currently- Formycon has four biosimilars in development
• Formycon focuses to treat ophthalmology- immunology- and other key chronic diseases covering the entire value chain from technical development to the clinical P-III & preparing the data for marketing approval

  | Ref: Formycon | Image: Formycon